Atopic dermatitis (AD) is a chronic inflammatory disease characterized by significant barrier disruption and intense pruritus. In recent years, there has been a growing number of targeted therapies in clinical development with a predominant focus on antagonizing Th2-mediated inflammation; however, these therapies are effective (IGA 0/1) in less than 50% of AD patients.
DermTech’s adhesive patch platform enables non-invasive gene expression analysis
Commentary by Grichnik, J. (2011) Br. J. Dermatol. 164(4):693-4